Patent
US 10,190,154REDUCED GRAPHENE OXIDE-BASED BIOSENSORS
Yingfu Li
US
Copyright © 2026 Matter42. All rights reserved.
Patent
Atlas literature
Patent
US 10,190,154Patent drawings and their descriptions. Click a drawing to enlarge it.
Figure 1 shows an in vitro selection of optimal DNA templates for RCA in one embodiment of the application. (a) In vitro selection scheme. (b) The 25 top 10 CTA sequences (SEQ ID NOs:1-10 respectively). Only the random- sequence domain is shown. (c) The sequence abundance (SA) and nucleotide …
Figure 2 shows determination of RCA efficiency (RE) of selective CTAs and CTBs in an embodiment of the application. (a) dPAGE analysis of digested RCA products obtained from varying time of RCA with CTA1, CTB1, and LB. The top band:(digested RCA monomer 60 nt); the bottom band: DNA 5 loading(control …
Figure 3 shows the RCA efficiency comparison of CTA₅ and CTA₅ mutants (SEQ ID NOs:5, 3 6, 37, 38, 39 and 40, respectively) in an exemplary embodiment of the application. ARU values that were used to derive RE values are provided in Table 2,
Figure 4 is a comparison of time-dependent amplicon production 15 using CTA₅ (grey line) and LB (black line) as the circular templates in an exemplary embodiment of the application. RPC: relative production of RCA product at a given template concentration. CT: circular template. RPC = 100 x C M, …
Figure 5 shows thrombin detection using CTA₅-assisted RCA in an exemplary embodiment of the application. (a) Detection strategy. (b) The sequences of circular templates (SEQ ID NO: 16 and 30, respectively) and the aptamer probe (SEQ ID NO:31). (c) Comparison of time-dependent amplicon formation …
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A biosensor comprising: a) reduced graphene oxide (rGO); and b) a nucleic acid probe absorbed on the rGO, the nucleic acid probe comprising an RCA primer sequence linked to a recognition moiety for an analyte. Original
(Previously amended) The biosensor of claim 1, wherein the recognition moiety is an aptamer that changes conformation in presence of the analyte, a DNAzyme that cleaves RNA in the presence of the analyte, or an antibody.
The biosensor of claim 1, wherein the analyte is a nucleic acid, protein or small molecule. Original
The biosensor of claim 1, wherein the recognition moiety for the analyte is at the 5' end of the probe and the RCA primer sequence is at the 3' end of the probe. Original
(Previously amended) A kit for detection of an analyte comprising (i) the biosensor of claim 1; (ii) a circular template comprising a sequence that is complementary to the RCA primer sequence; and (iii) one or more RCA reagents.
(Withdrawn-currently amended) A method for detection of an analyte comprising: a) providing the biosensor of claim 1; [[a]]b) contacting a sample suspected of comprising the analyte with the biosensor under conditions for binding the analyte to the recognition moiety and desorption of the nucleic acid probe from the rGO, to provide rGO and an analyte- nucleic acid probe complex; [[b]]c) separating the rGO from the analyte-nucleic acid probe complex; [[c]] d) contacting the analyte-nucleic acid probe with a circular template comprising a sequence that is complementary to the RCA primer sequence under RCA conditions to amplify the circular template; and [[d]]e) detecting a presence or an absence of the amplified circular template, wherein the presence of the amplified circular template indicates the presence of the analyte in the sample.
Canceled
(Withdrawn-currently amended) The method of claim[[s]] 15, wherein the AC rich nucleotide sequence is at least 70% AC rich, at least 80% AC rich, or at least 85% AC rich.
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
rGO-based biosensor
Materials described outside the worked examples.
reduced graphene oxide
nucleic acid probe
Measurements and analyses referenced in the patent, with their drawing references.
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 500–700 nm | — |
Duration |
Related documents with shared materials, methods, properties, or citations.
Patent
Atlas literature
Patent
US 10,190,154Patent drawings and their descriptions. Click a drawing to enlarge it.
Figure 1 shows an in vitro selection of optimal DNA templates for RCA in one embodiment of the application. (a) In vitro selection scheme. (b) The 25 top 10 CTA sequences (SEQ ID NOs:1-10 respectively). Only the random- sequence domain is shown. (c) The sequence abundance (SA) and nucleotide …
Figure 2 shows determination of RCA efficiency (RE) of selective CTAs and CTBs in an embodiment of the application. (a) dPAGE analysis of digested RCA products obtained from varying time of RCA with CTA1, CTB1, and LB. The top band:(digested RCA monomer 60 nt); the bottom band: DNA 5 loading(control …
Figure 3 shows the RCA efficiency comparison of CTA₅ and CTA₅ mutants (SEQ ID NOs:5, 3 6, 37, 38, 39 and 40, respectively) in an exemplary embodiment of the application. ARU values that were used to derive RE values are provided in Table 2,
Figure 4 is a comparison of time-dependent amplicon production 15 using CTA₅ (grey line) and LB (black line) as the circular templates in an exemplary embodiment of the application. RPC: relative production of RCA product at a given template concentration. CT: circular template. RPC = 100 x C M, …
Figure 5 shows thrombin detection using CTA₅-assisted RCA in an exemplary embodiment of the application. (a) Detection strategy. (b) The sequences of circular templates (SEQ ID NO: 16 and 30, respectively) and the aptamer probe (SEQ ID NO:31). (c) Comparison of time-dependent amplicon formation …
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A biosensor comprising: a) reduced graphene oxide (rGO); and b) a nucleic acid probe absorbed on the rGO, the nucleic acid probe comprising an RCA primer sequence linked to a recognition moiety for an analyte. Original
(Previously amended) The biosensor of claim 1, wherein the recognition moiety is an aptamer that changes conformation in presence of the analyte, a DNAzyme that cleaves RNA in the presence of the analyte, or an antibody.
The biosensor of claim 1, wherein the analyte is a nucleic acid, protein or small molecule. Original
The biosensor of claim 1, wherein the recognition moiety for the analyte is at the 5' end of the probe and the RCA primer sequence is at the 3' end of the probe. Original
(Previously amended) A kit for detection of an analyte comprising (i) the biosensor of claim 1; (ii) a circular template comprising a sequence that is complementary to the RCA primer sequence; and (iii) one or more RCA reagents.
(Withdrawn-currently amended) A method for detection of an analyte comprising: a) providing the biosensor of claim 1; [[a]]b) contacting a sample suspected of comprising the analyte with the biosensor under conditions for binding the analyte to the recognition moiety and desorption of the nucleic acid probe from the rGO, to provide rGO and an analyte- nucleic acid probe complex; [[b]]c) separating the rGO from the analyte-nucleic acid probe complex; [[c]] d) contacting the analyte-nucleic acid probe with a circular template comprising a sequence that is complementary to the RCA primer sequence under RCA conditions to amplify the circular template; and [[d]]e) detecting a presence or an absence of the amplified circular template, wherein the presence of the amplified circular template indicates the presence of the analyte in the sample.
Canceled
(Withdrawn-currently amended) The method of claim[[s]] 15, wherein the AC rich nucleotide sequence is at least 70% AC rich, at least 80% AC rich, or at least 85% AC rich.
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
rGO-based biosensor
Materials described outside the worked examples.
reduced graphene oxide
nucleic acid probe
Measurements and analyses referenced in the patent, with their drawing references.
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 500–700 nm | — |
Duration |
Related documents with shared materials, methods, properties, or citations.
Patent
Atlas literature
Patent
US 10,190,154Patent drawings and their descriptions. Click a drawing to enlarge it.
Figure 1 shows an in vitro selection of optimal DNA templates for RCA in one embodiment of the application. (a) In vitro selection scheme. (b) The 25 top 10 CTA sequences (SEQ ID NOs:1-10 respectively). Only the random- sequence domain is shown. (c) The sequence abundance (SA) and nucleotide …
Figure 2 shows determination of RCA efficiency (RE) of selective CTAs and CTBs in an embodiment of the application. (a) dPAGE analysis of digested RCA products obtained from varying time of RCA with CTA1, CTB1, and LB. The top band:(digested RCA monomer 60 nt); the bottom band: DNA 5 loading(control …
Figure 3 shows the RCA efficiency comparison of CTA₅ and CTA₅ mutants (SEQ ID NOs:5, 3 6, 37, 38, 39 and 40, respectively) in an exemplary embodiment of the application. ARU values that were used to derive RE values are provided in Table 2,
Figure 4 is a comparison of time-dependent amplicon production 15 using CTA₅ (grey line) and LB (black line) as the circular templates in an exemplary embodiment of the application. RPC: relative production of RCA product at a given template concentration. CT: circular template. RPC = 100 x C M, …
Figure 5 shows thrombin detection using CTA₅-assisted RCA in an exemplary embodiment of the application. (a) Detection strategy. (b) The sequences of circular templates (SEQ ID NO: 16 and 30, respectively) and the aptamer probe (SEQ ID NO:31). (c) Comparison of time-dependent amplicon formation …
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A biosensor comprising: a) reduced graphene oxide (rGO); and b) a nucleic acid probe absorbed on the rGO, the nucleic acid probe comprising an RCA primer sequence linked to a recognition moiety for an analyte. Original
(Previously amended) The biosensor of claim 1, wherein the recognition moiety is an aptamer that changes conformation in presence of the analyte, a DNAzyme that cleaves RNA in the presence of the analyte, or an antibody.
The biosensor of claim 1, wherein the analyte is a nucleic acid, protein or small molecule. Original
The biosensor of claim 1, wherein the recognition moiety for the analyte is at the 5' end of the probe and the RCA primer sequence is at the 3' end of the probe. Original
(Previously amended) A kit for detection of an analyte comprising (i) the biosensor of claim 1; (ii) a circular template comprising a sequence that is complementary to the RCA primer sequence; and (iii) one or more RCA reagents.
(Withdrawn-currently amended) A method for detection of an analyte comprising: a) providing the biosensor of claim 1; [[a]]b) contacting a sample suspected of comprising the analyte with the biosensor under conditions for binding the analyte to the recognition moiety and desorption of the nucleic acid probe from the rGO, to provide rGO and an analyte- nucleic acid probe complex; [[b]]c) separating the rGO from the analyte-nucleic acid probe complex; [[c]] d) contacting the analyte-nucleic acid probe with a circular template comprising a sequence that is complementary to the RCA primer sequence under RCA conditions to amplify the circular template; and [[d]]e) detecting a presence or an absence of the amplified circular template, wherein the presence of the amplified circular template indicates the presence of the analyte in the sample.
Canceled
(Withdrawn-currently amended) The method of claim[[s]] 15, wherein the AC rich nucleotide sequence is at least 70% AC rich, at least 80% AC rich, or at least 85% AC rich.
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
rGO-based biosensor
Materials described outside the worked examples.
reduced graphene oxide
nucleic acid probe
Measurements and analyses referenced in the patent, with their drawing references.
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 500–700 nm | — |
Duration |
Related documents with shared materials, methods, properties, or citations.
Patent
Atlas literature
Patent
US 10,190,154Patent drawings and their descriptions. Click a drawing to enlarge it.
Figure 1 shows an in vitro selection of optimal DNA templates for RCA in one embodiment of the application. (a) In vitro selection scheme. (b) The 25 top 10 CTA sequences (SEQ ID NOs:1-10 respectively). Only the random- sequence domain is shown. (c) The sequence abundance (SA) and nucleotide …
Figure 2 shows determination of RCA efficiency (RE) of selective CTAs and CTBs in an embodiment of the application. (a) dPAGE analysis of digested RCA products obtained from varying time of RCA with CTA1, CTB1, and LB. The top band:(digested RCA monomer 60 nt); the bottom band: DNA 5 loading(control …
Figure 3 shows the RCA efficiency comparison of CTA₅ and CTA₅ mutants (SEQ ID NOs:5, 3 6, 37, 38, 39 and 40, respectively) in an exemplary embodiment of the application. ARU values that were used to derive RE values are provided in Table 2,
Figure 4 is a comparison of time-dependent amplicon production 15 using CTA₅ (grey line) and LB (black line) as the circular templates in an exemplary embodiment of the application. RPC: relative production of RCA product at a given template concentration. CT: circular template. RPC = 100 x C M, …
Figure 5 shows thrombin detection using CTA₅-assisted RCA in an exemplary embodiment of the application. (a) Detection strategy. (b) The sequences of circular templates (SEQ ID NO: 16 and 30, respectively) and the aptamer probe (SEQ ID NO:31). (c) Comparison of time-dependent amplicon formation …
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
A biosensor comprising: a) reduced graphene oxide (rGO); and b) a nucleic acid probe absorbed on the rGO, the nucleic acid probe comprising an RCA primer sequence linked to a recognition moiety for an analyte. Original
(Previously amended) The biosensor of claim 1, wherein the recognition moiety is an aptamer that changes conformation in presence of the analyte, a DNAzyme that cleaves RNA in the presence of the analyte, or an antibody.
The biosensor of claim 1, wherein the analyte is a nucleic acid, protein or small molecule. Original
The biosensor of claim 1, wherein the recognition moiety for the analyte is at the 5' end of the probe and the RCA primer sequence is at the 3' end of the probe. Original
(Previously amended) A kit for detection of an analyte comprising (i) the biosensor of claim 1; (ii) a circular template comprising a sequence that is complementary to the RCA primer sequence; and (iii) one or more RCA reagents.
(Withdrawn-currently amended) A method for detection of an analyte comprising: a) providing the biosensor of claim 1; [[a]]b) contacting a sample suspected of comprising the analyte with the biosensor under conditions for binding the analyte to the recognition moiety and desorption of the nucleic acid probe from the rGO, to provide rGO and an analyte- nucleic acid probe complex; [[b]]c) separating the rGO from the analyte-nucleic acid probe complex; [[c]] d) contacting the analyte-nucleic acid probe with a circular template comprising a sequence that is complementary to the RCA primer sequence under RCA conditions to amplify the circular template; and [[d]]e) detecting a presence or an absence of the amplified circular template, wherein the presence of the amplified circular template indicates the presence of the analyte in the sample.
Canceled
(Withdrawn-currently amended) The method of claim[[s]] 15, wherein the AC rich nucleotide sequence is at least 70% AC rich, at least 80% AC rich, or at least 85% AC rich.
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
rGO-based biosensor
Materials described outside the worked examples.
reduced graphene oxide
nucleic acid probe
Measurements and analyses referenced in the patent, with their drawing references.
Figure 6 shows time-dependent digestion of RCA products made from CTA₁ using EcoRV in an exemplary embodiment of the application. TheRCA reaction was performed at 30 SVG 15091778.04-06-2016.IMP₃MHU₇PXXIFW3.SPEC.6.3.1271.621.1321.658.svg 0.123 0.167 Chemistry Black and white for 20 m in in 50 pL of …
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | 500–700 nm | — |
Duration |
Related documents with shared materials, methods, properties, or citations.
aptamer
DNAzyme
phi29 DNA polymerase
thrombin-binding DNA aptamer
| — |
aptamer
DNAzyme
phi29 DNA polymerase
thrombin-binding DNA aptamer
| — |
aptamer
DNAzyme
phi29 DNA polymerase
thrombin-binding DNA aptamer
| — |
aptamer
DNAzyme
phi29 DNA polymerase
thrombin-binding DNA aptamer
| — |